澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CLARITY PHARMACEUTICALS LTD

3.690

-0.070-1.86%

成交量：43.28萬

成交額：160.53萬

市值：13.73億

市盈率：-18.32

高：3.790

開：3.770

低：3.660

收：3.760

52周最高：5.870

52周最低：1.430

股本：3.72億

流通股本：2.74億

量比：1.04

換手率：0.16%

股息：- -

股息率：- -

每股收益(TTM):-0.201

每股收益(LYR):-0.201

淨資產收益率：-54.37%

總資產收益率：-33.76%

市淨率：15.21

市盈率(LYR):-18.32

資料載入中...

總覽公司新聞資訊公告

Clarity Pharmaceuticals表示靶向銅診療產品及臨床開發項目不受美國100%關税影響

CLARITY PHARMACEUTICALS LTD確認美國臨床試驗的同位素及藥品製造商均設在美國本土

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CU6.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":3.69,"timestamp":1772064574567,"preClose":3.76,"halted":0,"volume":432807,"delay":0,"changeRate":-0.018617021276595702,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.201427,"marketStatus":"交易中","change":-0.07,"latestTime":"02-26 11:10:10 AEDT","open":3.77,"high":3.79,"low":3.66,"amount":1605264,"amplitude":0.034574,"askPrice":3.71,"askSize":8898,"bidPrice":3.69,"bidSize":1626,"shortable":3,"etf":0,"ttmEps":-0.201427,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772082000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":3.76,"openAndCloseTimeList":[[1772060400000,1772082000000]],"volumeRatio":1.043517,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-33.76%","roe":"-54.37%","lyrEps":-0.201427,"volumeRatio":1.043517,"shares":372030071,"dividePrice":0,"high":3.79,"amplitude":0.034574,"preClose":3.76,"low":3.66,"week52Low":1.43,"pbRate":"15.21","psRate":"145.07","week52High":5.87,"institutionHeld":0,"latestPrice":3.69,"committee":-0.690992,"eps":-0.201427,"divideRate":0,"volume":432807,"delay":0,"ttmEps":-0.201427,"open":3.77,"prevYearClose":3.38,"prevWeekClose":3.51,"prevMonthClose":3.07,"prevQuarterClose":3.38,"fiveDayClose":3.47,"twentyDayClose":3.2,"sixtyDayClose":3.61,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142166450","title":"Clarity Pharmaceuticals表示靶向銅診療產品及臨床開發項目不受美國100%關税影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1142166450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142166450?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856278,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals宣布，公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。\n该公司强调，尽管面临新的贸易政策挑战，其核心业务运营和产品开发计划仍将按既定方向推进，确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"1176194720","title":"CLARITY PHARMACEUTICALS LTD確認美國臨床試驗的同位素及藥品製造商均設在美國本土","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194720?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856277,"startTime":"0","endTime":"0","summary":"CLARITY PHARMACEUTICALS LTD日前宣布，该公司已确认为其美国临床试验站点提供服务的所有同位素和药物产品制造商均位于美国境内。\n这一确认表明，CLARITY PHARMACEUTICALS LTD在美国开展的临床试验项目将完全依托本土制造商的产能和服务，确保供应链的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}